Helsinn Group supports Satellite Symposium at 14th EADO Congress 2018 Helsinn Group supports Satellite Symposium at 14th EADO Congress 2018 Lugano, Switzerland, November 6, 2018 – Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products,...

Helsinn Group strengthens the Board with the appointment of Francesco Granata Helsinn Group strengthens the Board with the appointment of Francesco Granata  LUGANO, October 1, 2018: Helsinn Group, a Swiss pharmaceutical group focused on building quality cancer care products,...

Helsinn Therapeutics (U.S.) Inc. becomes the exclusive distributor of ALOXI® (palonosetron HCI) in the U.S. Helsinn Therapeutics (U.S.) Inc. becomes the exclusive distributor of ALOXI® (palonosetron HCI) in the U.S. Iselin, NJ, USA, June 28, 2018 – Helsinn Therapeutics (U.S.) Inc., the U.S. subsidiary of...

The US Supreme Court Grants Review for Certiorari of a Federal Circuit Panel Ruling that US Patent Protection for Aloxi® in the US Market was Invalid The US Supreme Court Grants Review for Certiorari of a Federal Circuit Panel Ruling that US Patent Protection for Aloxi® in the US Market was Invalid Lugano, Switzerland, June 26, 2018 – The United...